Assessing the Evidence for Circulating Tumor HPV DNA in Patients With Oropharyngeal Cancer

JAMA Oncol. 2024 Aug 1;10(8):1021-1022. doi: 10.1001/jamaoncol.2024.1821.

Authors

Nancy Y Lee¹, Luc G T Morris², Maximilian Diehn³

Affiliations

¹ Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
² Immunogenomics and Precision Oncology Platform, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
³ Stanford University, Stanford, California.

PMID: 38935364
DOI: 10.1001/jamaoncol.2024.1821

No abstract available

Plain language summary

This Viewpoint evaluates the use of tumor tissue–modified human papillomavirus (HPV) DNA in identifying minimal residual disease.

MeSH terms

Circulating Tumor DNA / blood
Circulating Tumor DNA / genetics
DNA, Viral* / blood
Female
Humans
Male
Oropharyngeal Neoplasms* / virology
Papillomaviridae / genetics
Papillomavirus Infections* / complications
Papillomavirus Infections* / virology

Substances

DNA, Viral
Circulating Tumor DNA